SpaceX's Lockup Wall Meets a Reopened IPO Window

The IPO market spent the first half of 2026 in overdrive. U.S. equity new issuance reached $307.7 billion in aggregate proceeds across 192 IPOs (including SPACs) in H1, and the 203 announced IPOs year-to-date put the market on its third-highest clip of the last decade^[1]. The SEC’s Division of Economic and Risk Analysis published updated statistics on July 1 highlighting the increase in IPOs and proceeds raised^[1].

But the centerpiece — SpaceX’s record $86 billion IPO — is already wobbling. And the pipeline now filing in behind it is stepping onto a market whose plumbing has quietly changed.

SpaceX: The Supply Wall

SpaceX priced its IPO at $135 per share on June 11, 2026, with trading beginning the next day. Only about 639 million shares — roughly 5% of total shares outstanding — were sold into the offering^[2]. The stock rocketed to an intraday high of $225.64 on June 16, valuing the company at approximately $2.64 trillion on paper^[2].

Then gravity set in. By Thursday, July 17, SpaceX closed at $131.11 — down 42% from that peak and below the $135 IPO price — after declining in eight of nine sessions^[2]. Multiple reports on July 21 confirm the stock remains under pressure as lockup expirations approach^[3].

What makes SpaceX’s structure unusual is its phased lockup. Rather than a standard 180-day cliff, the S-1 built in a series of release valves^[4]:

• After Q2 earnings (projected August 6 per FactSet): insiders can sell up to 20% of their eligible locked shares. If the stock closes at least 30% above the IPO price ($175.50) on a sufficient number of trading days around the earnings release, an additional 10% unlocks.
• Rolling schedule at 70, 90, 105, 120, and 135 days post-IPO: another 7% unlocks at each interval.
• After Q3 earnings (three months through September): an additional 28% can be sold.
• At 180 days: whatever remains is fully released.
• Elon Musk remains locked up and cannot participate in any early-release provisions^[4].

The scale is the issue. According to SEC filings, up to 1.37 billion shares could become tradable starting in the days after SpaceX reports second-quarter results — 911.5 million Class A shares plus up to 455.8 million conditional shares if the price condition is met^[2]. The IPO itself involved only 639 million shares. The first lockup expiration alone could roughly quadruple the supply of tradable SpaceX stock^[2].

This was by design. CNBC reported that the phased structure was crafted to accelerate Nasdaq-100 inclusion by expanding the free float sooner, which would trigger forced buying from index funds and institutional benchmark-trackers^[4]. The bet was that index-inclusion demand would absorb the insider supply. Whether that equilibrium holds at $131 — 25% below the $175.50 conditional threshold — is the open question.

The IPO Window Stays Open

While SpaceX absorbs the spotlight, the new-issue pipeline is actively filing behind it. The current IPO calendar shows a meaningful mix:

Sources: StockAnalysis.com IPO calendar^[5], Renaissance Capital^[6][7], IPOScoop^[8]

The two marquee names at the end of July carry the most signal.

Jersey Mike’s Subs (JMKE) set terms on July 20 for a $1.0 billion IPO — 43.5 million shares at $21–$25, with 68% of the offering as secondary shares from existing holders^[6]. The Blackstone-backed sandwich chain, which traces its roots to 1956 on the Jersey Shore, operates over 3,000 franchised locations and reported $742 million in revenue^[5][6]. At the $23 midpoint, the company would command a valuation of approximately $7.9 billion^[6]. Blackstone’s COO Jonathan Gray flagged Jersey Mike’s as one of nine companies the firm hopes to list this year^[6].

Reformation (REF), the Permira-backed sustainable womenswear brand, set terms for a $225 million offering — 14.1 million shares at $15–$17^[7]. The company reported $507 million in revenue last year and operates 66 stores^[7]. At the midpoint, Reformation would be valued at roughly $1 billion^[7].

Scribe Therapeutics (SCTX), a Phase 1 CRISPR biotech targeting cardiovascular and metabolic diseases, expects net proceeds of about $96 million if it prices at the $14 midpoint of its $13–$15 range^[8]. The Bay Area company filed its S-1 on July 2 and its S-1/A amendment on July 10, with trading expected July 24^[8].

The mix matters. A SPAC-heavy calendar signals a market where sponsors are testing appetite but issuers are holding back. Two consumer-facing companies and a biotech pricing in the same two-week window suggests broader risk appetite than the first-half mega-deal narrative implied. General Atlantic’s capital markets team noted that the next phase of the IPO comeback “may be defined less by mega-deals themselves than by what follows: a broader opening incorporating mid-cap issuers, underrepresented sectors, and markets beyond this year’s busiest geographies”^[1].

Market Structure: The Ground Is Shifting

The issuance surge is happening on a market whose internal mechanics have changed.

Flow fragility. Scott Rubner, now at Citadel Securities’ Global Market Intelligence team, flagged in a May 18 report titled “Flow Fragility” that the S&P 500 had risen approximately 17% from its March 30 low, adding roughly $10 trillion in market capitalization, and that he was becoming “more tactically cautious” about a potential flow-of-funds unwind^[9]. In an April report, he noted the Nasdaq had been on a 10-day winning streak with the S&P up nearly 10%, adding about $5.5 trillion^[9]. His July research noted that retail investors are “bigger than they’ve ever been” and are starting to “trade like institutions”^[9].

Zero-day options. 0DTE (zero-days-to-expiry) options now drive 59% of SPX options volume^[9]. This intraday hedging and speculation layer amplifies end-of-day gamma flows and can produce volatility spikes that are mechanical rather than fundamental.

Extreme dispersion. Hedge funds are positioning for a volatility reversal as market dispersion reaches extreme levels^[10]. The selling in technology and semiconductor names over recent weeks has been “violent” — potentially forced liquidation rather than organic selling^[10]. Korean semiconductor volatility has spilled into U.S. markets, though Wall Street has absorbed the impact with only modest losses so far^[10].

Rangebound with tail risk. The S&P 500 has been trading in a range, with options traders shifting to a risk-on stance but with diminishing tailwinds^[10]. Meanwhile, JPMorgan research flagged that deleveraging is only halfway done^[10]. Mott Capital Management warned on July 13 that market imbalances raise the risk of a volatility unwind^[10].

The structural read: the market absorbed an enormous first-half supply of new equity ($307.7 billion in proceeds^[1]) while passive flows, 0DTE options, and retail activity amplified volume. That combination held — until semiconductor-driven dispersion and the SpaceX post-IPO selloff started testing the edges.

The Secondary Market Is Quietly Active Too

Beyond IPOs, the secondary offering and buyback machinery continues to turn. GlobalFoundries (GFS) completed a secondary offering in March 2026 — Mubadala Technology Investment Company sold 27.3 million ordinary shares at $42.00 per share (approximately $840 million), with GlobalFoundries concurrently repurchasing $300 million of its own shares^[11]. Docebo (DCBO) announced a substantial issuer bid on July 17 alongside preliminary Q2 results^[12]. Zealand Pharma reported ongoing buyback transactions for week 29 of 2026 on July 20^[12].

The concurrent buyback pattern — where issuers pair secondary sales with repurchases — is a mechanism to absorb some of the supply overhang at the deal level. SpaceX’s phased lockup serves a similar function at scale: instead of a single cliff, the release is staggered to let the market digest supply incrementally. But staggered or not, 1.37 billion shares is a large number.

What to Watch Next

• SpaceX Q2 earnings (projected August 6): This is the trigger for the first lockup release. The 20% tranche unlocks after the report. Whether the stock is above or below $175.50 determines whether the conditional 10% also releases. At $131.11, the conditional threshold is 34% away — far out of reach unless the stock rallies sharply before earnings^[2].

• Jersey Mike’s (JMKE) and Reformation (REF) pricing — July 30: The first consumer-sector IPOs to test the post-SpaceX window. If both price within range and trade well, it signals the new-issue window remains open despite the mega-deal overhang. If either cuts price or postpones, the window may be narrowing.

• Semiconductor dispersion and volatility: The forced-selling hypothesis in chip names^[10] and the Korean volatility spillover^[10] are the macro-structure risks that could tighten the window independently of any single deal. Watch whether the S&P 500 breaks out of its range or if dispersion narrows.

• 0DTE and gamma flows around earnings season: With Q2 earnings reports accelerating, intraday volatility from zero-day options could amplify moves in both directions. The 59% 0DTE share of SPX volume^[9] means that earnings-day reactions may overshoot before settling.

• SEC and exchange rule developments: Nasdaq’s “fast entry” rules for new listings^[4] and any further SEC market-structure initiatives will shape how quickly newly public companies attract index-driven demand — a key variable for the IPO pipeline’s pricing power.

The trajectory is this: a record IPO just broke below its offer price, a wall of locked supply is weeks away, the new-issue calendar is pushing forward with real companies at scale, and the market’s internal plumbing has become more flow-sensitive than at any point in recent memory. How much of that supply the market can absorb — and at what price — will define whether the 2026 IPO comeback’s second half looks like the first.